Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Robert McQueen to Humans

This is a "connection" page, showing publications Robert McQueen has written about Humans.

 
Connection Strength
  
 
 
0.557
  
  1. Zemplenyi AT, Chen NC, Anderson KE, Adamson B, DiStefano MJ, Nair KV, McQueen RB. Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab. Pharmacoeconomics. 2025 Sep; 43(9):1147-1160.
    View in: PubMed
    Score: 0.024
  2. Zemplenyi A, Leonard J, Wright GC, DiStefano MJ, Nair K, Anderson KE, McQueen RB. Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model. Pharmacoeconomics. 2025 May; 43(5):583-594.
    View in: PubMed
    Score: 0.023
  3. Anderson KE, Chaiyakunapruk N, Gutierrez EJ, Schmutz HW, Rose MR, Brixner D, McQueen RB. State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization. Health Aff (Millwood). 2024 08; 43(8):1137-1146.
    View in: PubMed
    Score: 0.023
  4. DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180.
    View in: PubMed
    Score: 0.022
  5. DiStefano MJ, Zemplenyi A, McQueen RB. Assessing clinical benefit in the Medicare Drug Price Negotiation Program: A 2-step approach for improving transparency, consistency, and meaningful patient engagement. J Manag Care Spec Pharm. 2024 Mar 01; 30(3):252-258.
    View in: PubMed
    Score: 0.022
  6. Zemplenyi A, Leonard J, DiStefano MJ, Anderson KE, Wright GC, Mendola ND, Nair K, McQueen RB. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. Pharmacoeconomics. 2024 Mar; 42(3):319-328.
    View in: PubMed
    Score: 0.021
  7. McQueen RB, Inotai A, Zemplenyi A, Mendola N, Németh B, Kalo Z. Multistakeholder Perceptions of Additional Value Elements for United States Value Assessment of Health Interventions. Value Health. 2024 01; 27(1):15-25.
    View in: PubMed
    Score: 0.021
  8. McQueen RB, Anderson KE, Levy JF, Carlson JJ. Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? Pharmacoeconomics. 2023 03; 41(3):321-327.
    View in: PubMed
    Score: 0.020
  9. McQueen RB, Baum SJ, Louie MJ, Sasiela WJ, Bilitou A, Shah H, Nash B, Gillard KK, Ray KK. Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins. Am J Cardiovasc Drugs. 2023 Jan; 23(1):67-76.
    View in: PubMed
    Score: 0.020
  10. Mendola ND, Oehrlein E, Perfetto EM, Westrich K, McQueen RB. Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States. J Manag Care Spec Pharm. 2022 Oct; 28(10):1190-1196.
    View in: PubMed
    Score: 0.020
  11. McQueen RB, Slejko JF. Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment. Pharmacoeconomics. 2021 04; 39(4):379-382.
    View in: PubMed
    Score: 0.018
  12. Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB. A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. Pharmacoeconomics. 2020 11; 38(11):1201-1218.
    View in: PubMed
    Score: 0.017
  13. Carlson JJ, Brouwer ED, Kim E, Wright P, McQueen RB. Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation. Value Health. 2020 12; 23(12):1523-1533.
    View in: PubMed
    Score: 0.017
  14. McQueen RB. What Value Does the NCCN Affordability Rating Really Provide to Patients, Providers, and Society? Pharmacoeconomics. 2020 07; 38(7):733-735.
    View in: PubMed
    Score: 0.017
  15. McQueen RB, Geno Rasmussen C, Waugh K, Frohnert BI, Steck AK, Yu L, Baxter J, Rewers M. Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado. Diabetes Care. 2020 07; 43(7):1496-1503.
    View in: PubMed
    Score: 0.017
  16. McQueen RB, Whittington MD, Chapman RH, Kumar VM, Campbell JD. Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States". Pharmacoeconomics. 2019 07; 37(7):963-964.
    View in: PubMed
    Score: 0.016
  17. McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations. Pharmacoeconomics. 2018 08; 36(8):957-971.
    View in: PubMed
    Score: 0.015
  18. McQueen RB, Breton MD, Craig J, Holmes H, Whittington MD, Ott MA, Campbell JD. Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England. J Diabetes Sci Technol. 2018 09; 12(5):992-1001.
    View in: PubMed
    Score: 0.015
  19. McQueen RB, Farahbakhshian S, Bell KF, Nair KV, Saseen JJ. Economic burden of comorbid chronic kidney disease and diabetes. J Med Econ. 2017 Jun; 20(6):585-591.
    View in: PubMed
    Score: 0.013
  20. McQueen RB. Capsule Commentary on Duru et al., Adherence to Metformin, Statins, and ACE/ARBs Within the Diabetes Health Plan (DHP). J Gen Intern Med. 2015 Nov; 30(11):1697.
    View in: PubMed
    Score: 0.012
  21. McQueen RB, Nair KV, Vollmer TL, Campbell JD. Incorporating real-world clinical practice in multiple sclerosis economic evaluations. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):869-72.
    View in: PubMed
    Score: 0.012
  22. McQueen RB, Breton MD, Ott M, Koa H, Beamer B, Campbell JD. Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada. J Diabetes Sci Technol. 2015 Aug 14; 10(2):366-77.
    View in: PubMed
    Score: 0.012
  23. McQueen RB, Livingston T, Vollmer T, Corboy J, Buckley B, Allen RR, Nair K, Campbell JD. Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study. J Manag Care Spec Pharm. 2015 Mar; 21(3):210-8b.
    View in: PubMed
    Score: 0.012
  24. Brett McQueen R, Perez-Nieves M, Todd Alonso G, Fan L, Hankosky ER, Shah VN, Yan Y, Ellis SL, Juneja R. Association between continuous glucose monitoring metrics and clinical outcomes in adults with type 1 diabetes in a real-world setting. Diabetes Res Clin Pract. 2024 Jun; 212:111690.
    View in: PubMed
    Score: 0.011
  25. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Libby AM, Campbell JD. Association between glycated hemoglobin and health utility for Type 1 diabetes. Patient. 2014; 7(2):197-205.
    View in: PubMed
    Score: 0.011
  26. Ferrat LA, Templeman EL, Steck AK, Parikh HM, You L, Onengut-Gumuscu S, Gottlieb PA, Triolo TM, Rich SS, Krischer J, McQueen RB, Oram RA, Redondo MJ. Type 1 diabetes prediction in autoantibody-positive individuals: performance, time and money matter. Diabetologia. 2025 Aug; 68(8):1709-1720.
    View in: PubMed
    Score: 0.006
  27. Bianchini ML, Rowan SE, Frost HM, Valuck R, McQueen RB, Anderson HD. Trends in Demographic Characteristics and Risk Factors Among Individuals With Syphilis in Colorado From 2011 to 2020. Sex Transm Dis. 2025 Jun 01; 52(6):345-351.
    View in: PubMed
    Score: 0.006
  28. DiStefano MJ, McQueen RB, Gao V, Klein MP, Snell-Bergeon JK, Polsky S. The Cost of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Type 1 Diabetes Pregnancies in the United States: A Cost-Consequences Analysis Using Real-World Evidence. Diabetes Technol Ther. 2025 Apr; 27(4):329-333.
    View in: PubMed
    Score: 0.006
  29. Hoffmann S, White AE, McQueen RB, Ahn JW, Gunn-Sandell LB, Scallan Walter EJ. Economic Burden of Foodborne Illnesses Acquired in the United States. Foodborne Pathog Dis. 2025 Jan; 22(1):4-14.
    View in: PubMed
    Score: 0.006
  30. Kluger BM, Katz M, Galifianakis NB, Pantilat SZ, Hauser JM, Khan R, Friedman C, Vaughan CL, Goto Y, Long SJ, Martin CS, Dini M, McQueen RB, Palmer L, Fairclough D, Seeberger LC, Sillau SH, Kutner JS. Patient and Family Outcomes of Community Neurologist Palliative Education and Telehealth Support in Parkinson Disease. JAMA Neurol. 2024 01 01; 81(1):39-49.
    View in: PubMed
    Score: 0.005
  31. Wright AC, Beaudoin FL, McQueen RB, Yeung K, Moradi A, Herron-Smith S, Gutierrez E, Lin GA, Pearson SD. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council. J Manag Care Spec Pharm. 2023 06; 29(6):692-698.
    View in: PubMed
    Score: 0.005
  32. Ahn JW, Scallan Walter E, White AE, McQueen RB, Hoffmann S. Identifying Sepsis From Foodborne Hospitalization: Incidence and Hospitalization Cost by Pathogen. Clin Infect Dis. 2022 09 14; 75(5):857-866.
    View in: PubMed
    Score: 0.005
  33. Rind DM, McQueen RB, Herron-Smith S, Herce-Hagiwara B, Gutierrez E, Campbell JD, Fluetsch N, Pearson SD. The effectiveness and value of tezepelumab for severe asthma. J Manag Care Spec Pharm. 2022 May; 28(5):577-580.
    View in: PubMed
    Score: 0.005
  34. Dhaliwal S, Hoffmann S, White A, Ahn JW, McQueen RB, Scallan Walter E. Cost of Hospitalizations for Leading Foodborne Pathogens in the United States: Identification by International Classification of Disease Coding and Variation by Pathogen. Foodborne Pathog Dis. 2021 11; 18(11):812-821.
    View in: PubMed
    Score: 0.005
  35. Mattingly TJ, McQueen RB, Lin PJ. Contextual Considerations and Recommendations for Estimating the Value of Alzheimer's Disease Therapies. Pharmacoeconomics. 2021 10; 39(10):1101-1107.
    View in: PubMed
    Score: 0.005
  36. Synnott PG, McQueen RB, Ollendorf DA, Campbell JD, Pearson SD. The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease. J Manag Care Spec Pharm. 2020 Jun; 26(6):782-785.
    View in: PubMed
    Score: 0.004
  37. Whittington MD, McQueen RB, Campbell JD. Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications. J Clin Oncol. 2020 02 01; 38(4):359-366.
    View in: PubMed
    Score: 0.004
  38. Carlson JJ, Walton SM, Basu A, Chapman RH, Campbell JD, McQueen RB, Pearson SD, Touchette DR, Veenstra D, Whittington MD, Ollendorf DA. Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States. Pharmacoeconomics. 2019 11; 37(11):1321-1327.
    View in: PubMed
    Score: 0.004
  39. Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J Antimicrob Chemother. 2019 08 01; 74(8):2405-2416.
    View in: PubMed
    Score: 0.004
  40. Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma. JAMA Netw Open. 2019 02 01; 2(2):e190035.
    View in: PubMed
    Score: 0.004
  41. Reynolds PM, Van Matre ET, Wright GC, McQueen RB, Burnham EL, Ho PJM, Moss M, Vandivier RW, Kiser TH. Evaluation of Prophylactic Heparin Dosage Strategies and Risk Factors for Venous Thromboembolism in the Critically Ill Patient. Pharmacotherapy. 2019 03; 39(3):232-241.
    View in: PubMed
    Score: 0.004
  42. Whittington MD, McQueen RB, Ollendorf DA, Chapman RH, Kumar VM, Synnott PG, Agboola F, Campbell JD. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. J Manag Care Spec Pharm. 2019 Jan; 25(1):80-87.
    View in: PubMed
    Score: 0.004
  43. Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. JAMA Pediatr. 2018 12 01; 172(12):1161-1168.
    View in: PubMed
    Score: 0.004
  44. Whittington MD, McQueen RB, Campbell JD. Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies. JAMA Pediatr. 2018 05 01; 172(5):409-410.
    View in: PubMed
    Score: 0.004
  45. Padula WV, McQueen RB, Pronovost PJ. Can Economic Model Transparency Improve Provider Interpretation of Cost-effectiveness Analysis? Evaluating Tradeoffs Presented by the Second Panel on Cost-effectiveness in Health and Medicine. Med Care. 2017 11; 55(11):909-911.
    View in: PubMed
    Score: 0.004
  46. Padula WV, McQueen RB, Pronovost PJ. Finding Resolution for the Responsible Transparency of Economic Models in Health and Medicine. Med Care. 2017 11; 55(11):915-917.
    View in: PubMed
    Score: 0.004
  47. Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, Haughney J, Henrichsen S, Hutton C, Infantino A, Lavorini F, Law LM, Lisspers K, Papi A, Ryan D, Ställberg B, van der Molen T, Chrystyn H. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. J Allergy Clin Immunol Pract. 2017 Jul - Aug; 5(4):1071-1081.e9.
    View in: PubMed
    Score: 0.003
  48. Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017 Feb; 118(2):220-225.
    View in: PubMed
    Score: 0.003
  49. van Boven JF, McQueen RB, Price DB. COPD case finding: effective, but also cost-effective? Lancet Respir Med. 2016 10; 4(10):e49.
    View in: PubMed
    Score: 0.003
  50. Campbell JD, McQueen RB, Libby AM, Spackman DE, Carlson JJ, Briggs A. Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information. Med Decis Making. 2015 07; 35(5):596-607.
    View in: PubMed
    Score: 0.003
  51. Bjornstad P, McQueen RB, Snell-Bergeon JK, Cherney D, Pyle L, Perkins B, Rewers M, Maahs DM. Fasting blood glucose--a missing variable for GFR-estimation in type 1 diabetes? PLoS One. 2014; 9(4):e96264.
    View in: PubMed
    Score: 0.003
  52. Campbell JD, McQueen RB, Briggs A. The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Ann Am Thorac Soc. 2014 Feb; 11 Suppl 2:S105-11.
    View in: PubMed
    Score: 0.003
  53. Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Am J Manag Care. 2013 Apr; 19(4):278-85.
    View in: PubMed
    Score: 0.003
  54. Libby AM, Ghushchyan V, McQueen RB, Slejko JF, Bainbridge JL, Campbell JD. Economic differences in direct and indirect costs between people with epilepsy and without epilepsy. Med Care. 2012 Nov; 50(11):928-33.
    View in: PubMed
    Score: 0.002
  55. Vande Griend JP, McQueen RB, Linnebur SA, Vondracek SF. Prescription ergocalciferol dosing for vitamin D repletion: a retrospective evaluation. Pharmacotherapy. 2012 Feb; 32(2):135-41.
    View in: PubMed
    Score: 0.002
  56. Nair KV, Corboy J, Kahler K, Allen RR, Ghushcyan V, McQueen RB, Bainbridge J, Dastani H, Mody-Patel N. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. Expert Rev Neurother. 2011 Jun; 11(6):787-98.
    View in: PubMed
    Score: 0.002
  57. Libby AM, Ghushchyan V, McQueen RB, Campbell JD. Economic grand rounds: psychological distress and depression associated with job loss and gain: the social costs of job instability. Psychiatr Serv. 2010 Dec; 61(12):1178-80.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)